Entry verification

You are about to enter a research catalogue.

Compounds shown on this site are sold strictly for laboratory and research use. They are not licensed medicines and are not intended for human or veterinary consumption. UK 18+ verification is required to enter.

Date of birth

Date of birth (day, month, year)
I do not qualify · leave the site

MHRA · ASA · ICO · UK GDPR aware

Amber-glass lyophilised vial of BPC-157 with white flip-cap and Optimal Lab cream-stripe label
fig. bpc-157 · 10mg · LYOPHILISEDJanoshik-tested
Structural Peptides

BPC-157

Synthetic pentadecapeptide derived from a sequence in gastric juice. Researched in animal models for tissue protection, fibroblast outgrowth, and angiogenesis.[1,2,3]

Variants
Select variant size
Quantity
1

PayPal or cash on collection · UK 18+ verification at dispatch · For laboratory research use only

HPLC chromatogram

Reverse-phase trace

Single peak at the expected retention time. Area % integration shown on every lot record. Per-lot chromatogram available on request from our supplier, Janoshik.

Reconstitution

Math, not dosing

For 10mg vial + 2 mL BAC water → concentration calculation on the dedicated calculator page. We provide research procedure only.

Selected research · BPC-157

  1. [1]Sikiric P, Seiwerth S, Rucman R, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design.Review of pentadecapeptide BPC 157 across animal models of gastrointestinal injury and tissue repair.PMID 21548867 →
  2. [2]Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. (2014). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology.In-vitro and in-vivo rat-tendon investigation of BPC 157 on fibroblast outgrowth and migration.PMID 21474670 →
  3. [3]Seiwerth S, Brcic L, Vuletic LB, et al. (2018). BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design.Review of BPC 157 angiogenic activity across multiple animal injury models.PMID 29879879 →

All references describe published research on the compound. They do not constitute clinical guidance or imply therapeutic benefit to any individual purchaser. For laboratory research use only.

Frequently bought together

All compounds →

TB-500

Synthetic thymosin beta-4 fragment. Studied in preclinical models examining wound-repair and cell-migration pathways. Frequently referenced alongside BPC-157 in research.

From £45.00

KPV

Tripeptide derived from alpha-MSH. Studied in preclinical anti-inflammatory and gastrointestinal research. Commonly referenced in research-compound groupings.

From £30.00

GHK-Cu

Copper peptide naturally occurring in plasma. Studied in preclinical research on skin remodelling, wound-repair pathways, and gene-expression modulation. Referenced in cellular-senescence research groupings.

From £30.00

Often stacked with BPC-157

All compounds →

TB-500

Synthetic thymosin beta-4 fragment. Studied in preclinical models examining wound-repair and cell-migration pathways. Frequently referenced alongside BPC-157 in research.

KPV

Tripeptide derived from alpha-MSH. Studied in preclinical anti-inflammatory and gastrointestinal research. Commonly referenced in research-compound groupings.

GHK-Cu

Copper peptide naturally occurring in plasma. Studied in preclinical research on skin remodelling, wound-repair pathways, and gene-expression modulation. Referenced in cellular-senescence research groupings.